...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Co-administration of meso 2,3-dimercaptosuccinic acid monoesters reduces arsenic concentration and oxidative stress in gallium arsenide exposed rats
【24h】

Co-administration of meso 2,3-dimercaptosuccinic acid monoesters reduces arsenic concentration and oxidative stress in gallium arsenide exposed rats

机译:共同施用内消旋2,3-二巯基琥珀酸单酯可降低砷化镓暴露大鼠中的砷浓度和氧化应激

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

1. Gallium arsenide (GaAs), a semiconductor, exerts toxicity as a result of its constitutive moieties; that is, gallium and arsenic that becomes dissociated after exposure. The present study focuses on reducing arsenic concentration from the target organs using monoesters of meso 2,3-dimercaptosuccinic acid (DMSA) either individually or in combination. 2. Animals were exposed to GaAs (0.0014 mol/kg, orally for 8 weeks) and then treated with monoisoamyl DMSA (MiAD-MSA), monocyclohexyl DMSA (MchDMSA) or monomethyl DMSA (MmDMSA) either individually (0.3 mmol/kg, orally) or in combination (0.15 mmol/kg each, orally) for five consecutive days. 3. GaAs exposure significantly inhibited blood d-aminolevuli-nic acid dehydrogenase (ALAD), suggesting alterations in the heme synthesis pathway. Whereas a significant increase in blood, liver and kidney reactive oxygen species accompanied by an increase in lipid peroxidation points to the involvement of oxidative stress in GaAs toxicity. 4. GaAs also significantly disturbed glutathione metabolism. Hepaticandrenalcatalaseactivitydecreasedsignificantly, whereas hepatic and renal superoxide dismutase activity, as well as serum transaminasesactivity, showed marginal increase. Treatment with MiADMSA in combination with MchDMSA showed better therapeutic efficacy compared with other treatments in the aforementioned variables. 5. Co-administration of MiADMSA with MchDMSA provided better therapeutic effects, including reduction of arsenic burden, compared with all other treatments.
机译:1.砷化镓(GaAs),一种半导体,由于其组成部分而具有毒性;也就是说,镓和砷在暴露后会解离。本研究的重点是通过单独或组合使用内消旋2,3-二巯基琥珀酸(DMSA)的单酯降低靶器官中的砷浓度。 2.动物分别暴露于GaAs(0.0014 mol / kg,口服8周),然后分别用单异戊基DMSA(MiAD-MSA),单环己基DMSA(MchDMSA)或一甲基DMSA(MmDMSA)单独治疗(0.3 mmol / kg口服) )或连续五天组合(每次口服0.15 mmol / kg)。 3. GaAs暴露显着抑制血液中的d-氨基乙酰丙酸脱氢酶(ALAD),表明血红素合成途径发生改变。血液,肝脏和肾脏的活性氧显着增加,同时脂质过氧化作用增加,表明氧化应激与GaAs毒性有关。 4. GaAs还显着干扰谷胱甘肽的代谢。肝和肾过氧化氢酶的活性显着降低,而肝和肾超氧化物歧化酶的活性以及血清转氨酶的活性则显示出一定程度的增加。在上述变量中​​,与其他治疗相比,与其他治疗相比,用MiADMSA结合MchDMSA进行治疗显示出更好的治疗效果。 5.与所有其他治疗方法相比,MiADMSA与MchDMSA的共同给药可提供更好的治疗效果,包括减少砷负担。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号